Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2018-10-30

Clinical Trial Update: Linagliptin Inpatient Trial [Phase 4]

View source ↗

Summary

Phase 4 inpatient trial of linagliptin for type 2 diabetes has completed, with results posted on 2018-10-30. The study was sponsored by Emory University.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Tradjenta (Linagliptin)

Snippet

Sponsor: Emory University | Conditions: Type 2 Diabetes | Phase 4 | Status: COMPLETED | Results posted: 2018-10-30